Business Context and Reporting Period
Replimune Group, Inc. filed this Form 8-K to report an equity financing transaction entered into on June 8, 2020. The company is a biotechnology issuer listed on Nasdaq under the symbol REPL. The report was signed June 10, 2020.
Transaction and Key Financial Metrics
- The company agreed to sell 2,826,088 shares of common stock at $23.00 per share.
- The company also agreed to sell pre-funded warrants to purchase 1,521,738 common shares at $22.9999 per warrant, with an exercise price of $0.0001 per share.
- The underwriters received a 30-day option to purchase up to 652,173 additional common shares.
- Expected net proceeds are approximately $93.7 million, after underwriting discounts, commissions, and estimated offering expenses, assuming the overallotment option is not exercised.
- The offering was expected to close on June 11, 2020, subject to customary closing conditions.
- The filing provides no revenue, profit, cash flow, margin, debt, or liquidity metrics for a comparable reporting period.
Material Changes Versus the Prior Comparable Period
The filing does not provide prior-period operating or financial results. The principal disclosed change is the planned increase in cash resources from the approximately $93.7 million net offering proceeds, subject to closing.
Guidance, Outlook, Risks, and Unusual Items
- Pre-funded warrants are exercisable after issuance and include beneficial ownership limitations generally capped at 9.99%, with increases up to 19.99% permitted following at least 61 days’ prior notice.
- The offering was made under the company’s effective Form S-3 shelf registration statement.
- Completion of the offering and the expected net proceeds were forward-looking matters subject to closing conditions and other risks.
- The company cautioned that actual results could differ materially because of risks described in its SEC filings and the offering prospectus materials.
- The filing does not specify the intended use of proceeds beyond the transaction disclosure.
Investor Verification Items
- Verify that the offering closed on or around June 11, 2020 and determine the final proceeds received.
- Check whether the underwriters exercised their 30-day option for additional shares.
- Review the final prospectus supplement for use of proceeds, dilution, and updated risk factors.
- Assess the potential dilution from the common shares and pre-funded warrants.
- Review subsequent SEC filings for the company’s post-financing cash balance, liquidity runway, and operating plans.